---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-020535"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2022-10-31T23:59:59+00:00"
generated_at: "2026-06-22T21:50:56.573254+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Galecto GB1211 reduces signs of liver impairment in GULLIVER-2 trial; data presented at AASLD

## Summary
- GB1211 well-tolerated with predictable PK; showed reductions in liver enzymes and FibroScan, indicating decreased inflammation and steatosis.
- Part 2 data selected as 'Best of The Liver Meeting' in NASH/NAFLD category.
- Preclinical rabbit model: GB1211 significantly reduced inflammation, fibrosis, and fat vs control.
- Galecto to host webinar Nov 8, 2022 at 8:00 AM ET to discuss expanded topline data.

## SEC filing metadata
- accession: 0000950170-22-020535
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2022-10-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000095017022020535/0000950170-22-020535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000095017022020535/glto-20221031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-020535
- JSON: https://secwatch.observer/filing/0000950170-22-020535.json
- Plain text: https://secwatch.observer/filing/0000950170-22-020535.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.